Multicenter registry for adults with spontaneous subarachnoid hemorrhage

Multicenter Registry of Patients With Subarachnoid Hemorrhage

This project collects detailed information from adults who had a spontaneous subarachnoid hemorrhage to see which treatments and care patterns lead to better outcomes.

Quick facts

• Study type: Observational
• Enrollment: 1000 (estimated)
• Sex: All
• Sponsor: UMC Utrecht (Academic / other)
• Locations: 9 sites (Nijmegen, Gelderland and 8 other locations)
• Trial ID: NCT07482124 on ClinicalTrials.gov

What this trial studies

This is an observational multicenter registry that enrolls adults with spontaneous subarachnoid hemorrhage confirmed by CT or cerebrospinal fluid analysis. Participating centers in the Netherlands will record patient characteristics, diagnostic findings, treatments, complications, and functional outcomes. The registry will combine these data to identify which treatment strategies and clinical factors are associated with better or worse recovery. There are no experimental interventions; the project uses real-world clinical data to guide future care and research.

Who should consider this trial

Good fit: Adults aged 18 or older with spontaneous subarachnoid hemorrhage confirmed by non-contrast head CT showing blood in the basal cisterns or major fissures, or by spectrophotometric xanthochromia of cerebrospinal fluid, including aneurysmal and other specified nontraumatic etiologies.

Not a fit: Patients with traumatic, neoplastic, infection-related (except mycotic aneurysms), iatrogenic, or isolated convexity subarachnoid hemorrhage, and those not treated at the participating centers, would not be eligible and are unlikely to benefit directly from this registry.

Why it matters

Potential benefit: If successful, the registry could improve future patient care by identifying treatments and care patterns that produce better outcomes after subarachnoid hemorrhage.

How similar studies have performed: Other national and international SAH registries and cohort studies have previously identified important prognostic factors and influenced clinical practice, so this effort builds on established registry approaches.

Eligibility criteria

Inclusion Criteria:

* Age ≥ 18 years
* Spontaneous subarachnoid hemorrhage with blood in the basal cisterns and/or major fissures on non-contrast head computed tomography (CT), or xanthochromia of cerebrospinal fluid confirmed by spectrophotometric analysis.
* Eligible etiologies/patterns:

  * Aneurysmal SAH
  * SAH from other intracranial vascular malformation (e.g. AVM, dural AVF)
  * Perimesencephalic SAH
  * Non-perimesencephalic angiogram negative SAH
  * SAH from intracranial artery dissection

Exclusion Criteria:

* Traumatic, neoplastic, infection related (except mycotic aneurysms), or iatrogenic SAH
* Isolated convexity SAH

Where this trial is running

Nijmegen, Gelderland and 8 other locations

• Radboud University Medical Center — Nijmegen, Gelderland, Netherlands (Recruiting)
• Maastricht University Medical Center+ — Maastricht, Limburg, Netherlands (Recruiting)
• Elisabeth-Tweesteden Hospital — Tilburg, North Brabant, Netherlands (Recruiting)
• Amsterdam University Medical Center — Amsterdam, North Holland, Netherlands (Recruiting)
• Isala — Zwolle, Overijssel, Netherlands (Recruiting)
• University Medical Center Groningen — Groningen, Provincie Groningen, Netherlands (Recruiting)
• Erasmus University Medical Center — Rotterdam, South Holland, Netherlands (Recruiting)
• Haaglanden Medical Center — The Hague, South Holland, Netherlands (Recruiting)
• Utrecht University Medical Center — Utrecht, Utrecht, Netherlands (Recruiting)

Study contacts

• Study coordinator: P.B. van Wijngaarden, MD

Conditions Subarachnoid Hemorrhage, Spontaneous